Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
about
Use of rodents as models of human diseasesPhase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancerPhase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysisAnticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracilBiweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation studyBi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status.Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studiesEffect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthaseHypoestoxide inhibits tumor growth in the mouse CT26 colon tumor model.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinomaPhase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer.Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.Efficacy of S-1 in non-small cell lung cancer.Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation.Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent.Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease.Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.Preliminary trial of adjuvant surgery for advanced gastric cancer.Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
P2860
Q26822856-992B685A-6E1E-4F9A-8FB0-6910D797D08EQ33390208-9460634E-9DF8-43F6-BFD1-F111C3FD6DBDQ33403640-F8FEFA64-18C7-4D44-9EBD-C034DF65642BQ33594906-33846383-EF30-4000-A5C8-3C8FEE7231D8Q33884698-37F62711-A95B-4F6E-8B11-F7EFDFABC137Q33912151-E5515D91-64D2-48E5-A417-8B4B9D62A1A4Q34088371-EC695D6C-3DAF-4F0F-8FC8-DE3B97D0E6D3Q34204650-115C5FD2-8123-4AB5-9FE6-A5EF8E55CBF8Q34447512-1414A95E-93C3-44B2-A5E5-7497D99E32C1Q34604303-B1275E51-19F1-487F-8E0A-96174D086067Q35073353-4EFDB251-A66E-4ABA-861A-41AFC013D7DCQ36142392-A075A5F5-CCE3-4468-BDB9-85FCA39B4A31Q36179928-A184401A-55AB-423F-92E4-708953C8BA3EQ36614394-E3F91B9D-4BF3-47A6-BBEC-41CB107B32F1Q36615597-A22AAFDA-B652-4C79-87CB-ED149CC6F940Q36795339-1B4AC670-053E-4B28-AD7F-D03AFC39F041Q36940910-E7DDF8E5-E355-4410-A35D-D75DD5188FF9Q37142445-B963F1D3-80E6-461A-BCA1-3F3E9778D0C1Q37959113-0E5447D4-3E30-4DE6-A287-367D13C9914BQ38133562-7C202DB0-6488-40FE-9111-C4285A35C01CQ38238511-C14B8366-ECCD-4CBC-817E-061D72EA1ED8Q39433347-3892D998-1651-4086-B18F-76020F7810EAQ39924293-5F543F20-AC1A-4664-8B4F-4ADFB1146C7EQ40279396-6281E322-1B6A-49EC-BFC9-B15BDDED52DEQ41212632-BEAEF268-EF41-4F59-81A7-62FB25695CE6Q42323722-80C1B017-E877-4DFE-9579-4B3CF5574008Q45435712-3DD087F8-4CF4-4E7E-8B8C-2ED4B154C40FQ48052472-51A9BC37-B35E-4D44-9D8A-D01464F6AE3EQ49194716-1C774B16-45F9-422D-93A8-C5FD160A0048Q53803365-FDC65BB9-4826-439C-8173-29ADC543A705
P2860
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Synergistic effects of docetax ...... man gastric cancer cell lines.
@en
type
label
Synergistic effects of docetax ...... man gastric cancer cell lines.
@en
prefLabel
Synergistic effects of docetax ...... man gastric cancer cell lines.
@en
P2093
P356
P1476
Synergistic effects of docetax ...... man gastric cancer cell lines.
@en
P2093
Hirozumi Mizuiri
Kazuaki Tanabe
Kazuhiro Yoshida
Kazuo Konishi
Masakazu Fukushima
Takahisa Suzuki
Yoshiyuki Wada
P2860
P304
P356
10.1002/IJC.21879
P577
2006-08-01T00:00:00Z